Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

Video

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Related Content
Robert W. Mutter, MD

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
FDA

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Anne Favret, MD

Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer

April 12th 2024
Article
Matt Coffey, PhD, president, chief executive officer, Oncolytics Biotech

FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

April 12th 2024
Article